BMI Qualifications for GLP-1 Treatments To qualify for GLP-1 medications through Hormone Fitness, patients typically need to meet specific Body Mass Index (BMI) criteria: BMI of 30 or higher: Individuals classified as obese
Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis
This distribution mirrors the general GLP-1 market, where semaglutide dominates prescribing patterns
The peptide itself is only one part of the equation
Canadas patent has already lapsed, enabling potential launches as early as January 2026 Active litigation in India and China is unlikely to delay generic entry beyond March 20th 2026
Strengths and weaknesses The strengths of this substudy include the methods and design of SUSTAIN 8, a double-blind randomised clinical trial with a global population, relatively long treatment period of 52 weeks, and relevant head-to-head comparison with a glucose-lowering medication with demonstrated efficacy in type 2 diabetes
